This phase II/III trial is evaluating the safety and effectiveness of a new oral drug (TGR-1202) in combination with a type of immunotherapy (ublituximab) with or without chemotherapy (bendamustine) in patients with recurrent or refractory Non-Hodgkin's Lymphoma.
This trial is treating patients with Non-Hodgkin's Lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma
Commercial Sponsor
TG Therapeutics, Inc.
Summary
Participants in this trial will be randomised into one of three treating arms; receiving either an oral dose of TGR-1202 alone, in combination with intravenous ublituximab or in combination with ublituximab and intravenous bendamustine.
Recruiting Hospitals Read More